<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e94c0cff-48b4-4cb6-b7db-86013d3cf2c7"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">
         <br/>
      </content>
      <content styleCode="bold">These highlights do not include all the information needed to use </content>
      <content styleCode="bold">BREKIYA</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> safely and effectively. See full prescribing information for BREKIYA<sup>®</sup>.<br/>
         <br/>
      </content>
      <content styleCode="bold">BREKIYA<sup>®</sup> (dihydroergotamine mesylate) injection, for subcutaneous use</content>
      <content styleCode="bold">
         <br/>
Initial U.S. Approval: 1946</content>
   </title>
   <effectiveTime value="20250515"/>
   <setId root="cdbf5619-767f-4165-aec2-17bdd92d9ca2"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
            <name>Amneal Pharmaceuticals LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="860156658" root="1.3.6.1.4.1.519.1"/>
                        <name>Amneal Pharmaceuticals Private Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64896-509" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64896-509" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64896-509" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" displayName="sterilize" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64896-509" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3c9da8d8-0f39-4963-8386-b4562c1c3ef7"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250516"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64896-509" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>BREKIYA</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dihydroergotamine Mesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="81AXN7R2QT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIHYDROERGOTAMINE MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="436O5HM03C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DIHYDROERGOTAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="12EH9M7279" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHANESULFONIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1 "/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64896-509-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" displayName="SYRINGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" displayName="POUCH" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="4"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="64896-509-02" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20250516"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215400" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250516"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_bb7ceb11-60f8-401d-96f1-e2c3a6687b98">
               <id root="bdc7bae1-ed6d-489b-9d66-3c32acb8b4f4"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: PERIPHERAL ISCHEMIA
FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of BREKIYA with strong CYP3A4 inhibitors is contraindicated </content>
                     <content styleCode="bold">
                        <content styleCode="italics">[see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml>, <linkHtml href="#LINK_d6d8105e-1465-4636-b4a9-6a7edd29450c">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#LINK_7cdd1f9c-de24-47c9-9252-d4e99fcf42cd">Drug Interactions (7.1)</linkHtml>].</content>
                     </content>
                  </paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Serious and/or life-threatening peripheral ischemia has been associated with the co-administration of dihydroergotamine with strong CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of BREKIYA with strong CYP3A4 inhibitors is contraindicated </content>
                           <content styleCode="bold">
                              <content styleCode="italics">[see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml> and <linkHtml href="#LINK_d6d8105e-1465-4636-b4a9-6a7edd29450c">Warnings and Precautions (5.1)</linkHtml>].</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">
               <id root="9a18353e-58a3-4f84-b3e4-50d2746e4249"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>BREKIYA is indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.</paragraph>
                  <paragraph>
                     <content styleCode="underline"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use </content>
                  </paragraph>
                  <paragraph>BREKIYA is not indicated for the preventive treatment of migraine. </paragraph>
                  <paragraph>BREKIYA is not indicated for the management of hemiplegic migraine or migraine with brainstem aura.</paragraph>
               </text>
               <effectiveTime value="20250515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>BREKIYA is an ergotamine derivative indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults. (<linkHtml href="#LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">1</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>BREKIYA is not indicated for the preventive treatment of migraine or for the management of hemiplegic migraine or migraine with brainstem aura. (<linkHtml href="#LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">
               <id root="bd819fcf-b9c2-43b2-b229-ddeff8c47275"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>For subcutaneous injection only. (<linkHtml href="#LINK_839637f6-e501-4a24-b12f-88f7c726d964">2.1</linkHtml>)</item>
                           <item>Recommended dosage is 1 mg administered subcutaneously as a single 1 mL autoinjector. (<linkHtml href="#LINK_839637f6-e501-4a24-b12f-88f7c726d964">2.1</linkHtml>) </item>
                           <item>Do not exceed 3 mg (3 doses) in a 24-hour period. (<linkHtml href="#LINK_839637f6-e501-4a24-b12f-88f7c726d964">2.1</linkHtml>)</item>
                           <item>Do not exceed 6 mg (6 doses) in a week. (<linkHtml href="#LINK_839637f6-e501-4a24-b12f-88f7c726d964">2.1</linkHtml>)</item>
                           <item>Prior to initiation, a cardiovascular evaluation is recommended. (<linkHtml href="#LINK_87e1ae43-ee24-4683-88f8-741a9b58c475">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_839637f6-e501-4a24-b12f-88f7c726d964">
                     <id root="ce866013-39cf-45cb-9928-dc4e8cce3784"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>BREKIYA autoinjector is for subcutaneous injection only.</paragraph>
                        <paragraph>The recommended dose of BREKIYA is 1 mg administered subcutaneously via a single 1 mL autoinjector. The dose may be repeated, as needed, at 1-hour intervals to a total maximum of 3 mg (3 doses) in a 24-hour period. </paragraph>
                        <paragraph> Do not exceed 6 mg (6 doses) total in a week.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_87e1ae43-ee24-4683-88f8-741a9b58c475">
                     <id root="cb5b8b89-aa67-4111-8073-a0f5f0d8cc23"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Assessment Prior to First Dose</title>
                     <text>
                        <paragraph>Prior to initiation of BREKIYA, a cardiovascular evaluation is recommended <content styleCode="italics">[see <linkHtml href="#LINK_e48c6a70-d2a3-4590-bc8d-402e7eec0511">Warnings and Precautions (5.3)</linkHtml>]</content>. For patients with risk factors predictive of coronary artery disease who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of BREKIYA take place in the setting of an equipped healthcare facility.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d109a581-1854-4803-8a3c-31578bb26380">
                     <id root="59180e5c-18c8-417e-bd5b-e2493965db9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Important
Administration Instructions</title>
                     <text>
                        <paragraph>See the “Instructions for Use” for detailed steps for administering the subcutaneous injection using the autoinjector. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Preparation</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>BREKIYA is a prefilled, single-dose disposable autoinjector intended to be given subcutaneously into the skin of the middle thigh. </item>
                           <item>Rotate injection sites. Choose an injection site at least 2 inches away from the last injection site. </item>
                           <item>Do not inject into moles, scars, birthmarks, or areas where the skin is tender, bruised, red, or hard.</item>
                           <item>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Carefully examine the liquid medication for discoloration, cloudiness, floating flakes or particles. Administer only if clear and colorless.
    <paragraph>
                                 <content styleCode="underline">Administration</content>
                              </paragraph>
                           </item>
                           <item>Remove the red needle cap by pulling it straight off. </item>
                           <item>Position the autoinjector straight onto the cleaned injection site with the white safety guard resting on the skin. Push the autoinjector down and press and release the gray activation button to start the injection. A “click” will sound when the injection starts. </item>
                           <item>The autoinjector takes approximately 10 seconds to deliver the dose; when the viewing window is fully blocked (completely blue), the full dose has been administered.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">
               <id root="8dce7ff6-54ef-45bf-90ac-8235c04b8c0f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 1 mg/mL dihydroergotamine mesylate as a clear, colorless solution in a 1 mL single-dose autoinjector.</paragraph>
               </text>
               <effectiveTime value="20250515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 1 mg/mL dihydroergotamine mesylate as a 1 mL single-dose autoinjector. (<linkHtml href="#LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">
               <id root="a93e43e3-1cf7-4906-bd07-43bb3f5c0627"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>BREKIYA is contraindicated in patients:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>with concomitant use of strong CYP3A4 inhibitors <content styleCode="italics">[see <linkHtml href="#LINK_d6d8105e-1465-4636-b4a9-6a7edd29450c">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#LINK_7cdd1f9c-de24-47c9-9252-d4e99fcf42cd">Drug Interactions (7.1)</linkHtml>]</content>
                     </item>
                     <item>with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina <content styleCode="italics">[see <linkHtml href="#LINK_17df11b4-573c-4c7d-993d-6e6507ff5b6e">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>with uncontrolled hypertension <content styleCode="italics">[see <linkHtml href="#LINK_98a36d82-4475-4888-b9ab-5743f32c5ecb">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>with peripheral arterial disease </item>
                     <item>with sepsis </item>
                     <item>following vascular surgery </item>
                     <item>with severe hepatic impairment </item>
                     <item>with severe renal impairment</item>
                     <item>with known hypersensitivity to dihydroergotamine, ergot alkaloids, latex, or any of the ingredients in BREKIYA <content styleCode="italics">[see <linkHtml href="#LINK_ddda22cd-ca7b-4b7b-9a7e-2d01ba08a65c">Warnings and Precautions (5.9)</linkHtml>]</content>
                     </item>
                     <item>with recent use (i.e., within 24 hours) of other 5-HT1 agonists, ergotamine-containing or ergot-type medications <content styleCode="italics">[see <linkHtml href="#LINK_c962e338-c452-4a01-b05c-84d272adbf9e">Drug Interactions (7.2)</linkHtml>]</content>
                     </item>
                     <item>with concomitant use of peripheral and central vasoconstrictors because the combination may result in additive or synergistic elevation of blood pressure <content styleCode="italics">[see <linkHtml href="#LINK_98a36d82-4475-4888-b9ab-5743f32c5ecb">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Concomitant use of strong CYP3A4 inhibitors (<linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>)</item>
                           <item>Ischemic heart disease or coronary artery vasospasm (<linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>)</item>
                           <item>Uncontrolled hypertension, peripheral arterial diseases, sepsis, following vascular surgery, or severe hepatic or renal impairment (<linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>)</item>
                           <item>Concomitant use of other 5-HT<sub>1</sub> agonists or ergotamine-containing or ergot-type medications within 24 hours (<linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>)</item>
                           <item>Hypersensitivity to dihydroergotamine, ergot alkaloids, latex, or any of the ingredients in BREKIYA (4)</item>
                           <item>Concomitant use with peripheral and central vasoconstrictors (<linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_4e1684e1-bdaa-4046-ac6f-e2816f5fb48e">
               <id root="732f973a-3dc8-42bf-aa69-b06be3906f37"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <br/>
               </text>
               <effectiveTime value="20250515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Myocardial Ischemia and/or Infarction, Other Cardiac Adverse Reactions, and Fatalities: </content>In patients with risk factors predictive of coronary artery disease, consider first dose administration under medical supervision with an electrocardiogram. (<linkHtml href="#LINK_3d045550-60a7-4a3c-b87a-7bfd32a84abc">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Cerebrovascular Adverse Reactions and Fatalities:</content> Cerebrovascular hemorrhage, subarachnoid hemorrhage, and stroke have been reported; discontinue BREKIYA if suspected. (<linkHtml href="#LINK_e48c6a70-d2a3-4590-bc8d-402e7eec0511">5.3</linkHtml>) </item>
                           <item>
                              <content styleCode="italics">Other Vasospasm Related Adverse Reaction:</content> BREKIYA may cause vasospasm or elevation in blood pressure. Discontinue if signs or symptoms of vasoconstriction develop. (<linkHtml href="#LINK_17df11b4-573c-4c7d-993d-6e6507ff5b6e">5.4</linkHtml>, <linkHtml href="#LINK_98a36d82-4475-4888-b9ab-5743f32c5ecb">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Medication Overuse Headache: </content>Detoxification may be necessary. (<linkHtml href="#LINK_1dc5aa46-7e3d-4a71-a274-ad3f63e16ac0">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Preterm Labor: </content>Advise pregnant women of the risk. (<linkHtml href="#LINK_8cf32adc-f355-4c72-8643-bc76dc860acc">5.7</linkHtml>, <linkHtml href="#LINK_c7ddff79-330d-427b-b47b-400ef0464579">8.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Fibrotic Complication:</content> Pleural and retroperitoneal fibrosis have been reported following prolonged daily use of dihydroergotamine mesylate. Do not exceed the BREKIYA dosing guidelines or use for chronic daily administration. (<linkHtml href="#LINK_709f64c1-1cf9-4482-85af-e3ea101bf09e">5.8</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_d6d8105e-1465-4636-b4a9-6a7edd29450c">
                     <id root="3b2d68bf-9b27-4aa1-b705-5c4b34238582"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Peripheral Ischemia Following
Coadministration with Strong CYP3A4 Inhibitors</title>
                     <text>
                        <paragraph>Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine and strong CYP3A4 inhibitors.  Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or and ischemia of the extremities is increased. Hence, concomitant use of BREKIYA with strong CYP3A4 inhibitors is contraindicated <content styleCode="italics">[see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml> and <linkHtml href="#LINK_7cdd1f9c-de24-47c9-9252-d4e99fcf42cd">Drug Interactions (7.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3d045550-60a7-4a3c-b87a-7bfd32a84abc">
                     <id root="bf5f7ba1-9644-4b55-ac63-fe0c95146e4a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Myocardial Ischemia and/or
Infarction, Other Cardiac Adverse Reactions, and Fatalities</title>
                     <text>
                        <paragraph>The potential for cardiac adverse reactions exists with BREKIYA treatment. Serious adverse cardiac events, including some that have been fatal, have occurred following use of dihydroergotamine mesylate. These events have included acute myocardial infarction, life-threatening disturbances of cardiac rhythm (e.g., ventricular tachycardia and ventricular fibrillation), coronary artery vasospasm, and transient myocardial ischemia. </paragraph>
                        <paragraph>Prior to initiation of BREKIYA, a cardiovascular evaluation is recommended to determine if the patient is free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. If, during the cardiovascular evaluation, the patient’s medical history (including risk factors), or electrocardiographic investigation findings are consistent with coronary artery vasospasm or myocardial ischemia, BREKIYA should   not   be   administered <content styleCode="italics">[see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>For patients with risk factors predictive of coronary artery disease (e.g., hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of coronary artery disease, females who are surgically or physiologically postmenopausal, or males who are over 40 years of age) who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of BREKIYA take place in the setting of an equipped healthcare facility, unless the patient has previously received dihydroergotamine. During the interval immediately following the first use of BREKIYA, an electrocardiogram is recommended in those patients with risk factors because ischemia can occur in the absence of clinical symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e48c6a70-d2a3-4590-bc8d-402e7eec0511">
                     <id root="27a455db-beeb-48c2-aad8-183eb2937dff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Cerebrovascular Adverse Reactions
and Fatalities</title>
                     <text>
                        <paragraph>The potential for adverse cerebrovascular events exists with BREKIYA treatment. Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with dihydroergotamine mesylate; and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the dihydroergotamine mesylate having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine, when they were not. It should be noted that patients with migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, hemorrhage, transient ischemic attack). Discontinue BREKIYA if a cerebrovascular event is suspected.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_17df11b4-573c-4c7d-993d-6e6507ff5b6e">
                     <id root="5fafa820-db66-4814-930b-a5b0b8bd12d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Other Vasospasm-Related Adverse
Reactions</title>
                     <text>
                        <paragraph>BREKIYA, like other ergot alkaloids, may cause vasospastic reactions other than coronary artery vasospasm. Myocardial, peripheral vascular, and colonic ischemia have been reported with dihydroergotamine mesylate.</paragraph>
                        <paragraph>Dihydroergotamine associated vasospastic phenomena may also cause muscle pains, numbness, coldness, pallor, and cyanosis of the digits. In patients with compromised circulation, persistent vasospasm may result in gangrene or death. BREKIYA should be discontinued immediately if signs or symptoms of vasoconstriction develop.</paragraph>
                        <paragraph>Patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud’s syndrome following the use of any 5-HT agonist, including BREKIYA, should be evaluated by a healthcare provider.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_98a36d82-4475-4888-b9ab-5743f32c5ecb">
                     <id root="ba9df998-fc08-4157-be53-c88a10bcc780"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Increase in Blood Pressure</title>
                     <text>
                        <paragraph>Significant elevation in blood pressure has been reported on rare occasions in patients with and without a history of hypertension treated with dihydroergotamine mesylate. BREKIYA is contraindicated in patients with uncontrolled hypertension <content styleCode="italics">[see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph> An 18% increase in mean pulmonary artery pressure was seen following dosing with another 5-HT<sub>1</sub> agonist in a study evaluating subjects undergoing cardiac catheterization.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1dc5aa46-7e3d-4a71-a274-ad3f63e16ac0">
                     <id root="89b657ad-c186-4aff-9a13-b41903d2b2e4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Medication Overuse Headache</title>
                     <text>
                        <paragraph>Overuse of acute migraine drugs (e.g., ergotamines, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (i.e., medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8cf32adc-f355-4c72-8643-bc76dc860acc">
                     <id root="30e2a911-d51a-40bd-9ca1-57c302d52c41"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Preterm Labor</title>
                     <text>
                        <paragraph>Based on the mechanism of action of dihydroergotamine and findings from the published literature, BREKIYA may cause preterm labor. Avoid use of BREKIYA during pregnancy <content styleCode="italics">[see <linkHtml href="#LINK_c7ddff79-330d-427b-b47b-400ef0464579">Use in Specific Populations (8.1)</linkHtml> and <linkHtml href="#LINK_341097fb-f403-4324-b506-0e5f01fc8f3a">Clinical Pharmacology (12.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_709f64c1-1cf9-4482-85af-e3ea101bf09e">
                     <id root="8a940001-2fb8-491b-b05d-a6b499783b6b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Fibrotic Complications</title>
                     <text>
                        <paragraph>The potential for fibrotic complications exists with BREKIYA treatment. There have been reports of pleural and retroperitoneal fibrosis in patients following prolonged daily use of dihydroergotamine mesylate. Rarely, prolonged daily use of other ergot alkaloid drugs has been associated with cardiac valvular fibrosis. Rare cases have also been reported in association with the use of dihydroergotamine mesylate; however, in those cases, patients also received drugs known to be associated with cardiac valvular fibrosis.</paragraph>
                        <paragraph>Administration of BREKIYA should not exceed the dosing guidelines and should not be used for chronic daily administration <content styleCode="italics">[see <linkHtml href="#LINK_839637f6-e501-4a24-b12f-88f7c726d964">Dosage and Administration (2.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ddda22cd-ca7b-4b7b-9a7e-2d01ba08a65c">
                     <id root="6c2a88d7-afb8-46eb-b7f4-62618aceb17b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Hypersensitivity</title>
                     <text>
                        <paragraph>The rigid needle shield of the BREKIYA autoinjector contains a needle cover (located inside the cap) that contains dry natural rubber, which is made from latex. BREKIYA is contraindicated in patients who have previously shown hypersensitivity to ergot alkaloids or latex.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9440e503-baf7-441c-991f-439bc85d32c3">
               <id root="fa0c912c-bae1-4061-b18e-411554759e3f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Peripheral Ischemia Following Coadministration with Strong CYP3A4 Inhibitors <content styleCode="italics">[see <linkHtml href="#LINK_bb7ceb11-60f8-401d-96f1-e2c3a6687b98">Boxed Warning</linkHtml> and <linkHtml href="#LINK_d6d8105e-1465-4636-b4a9-6a7edd29450c">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Myocardial Ischemia and/or Infarction, Other Adverse Cardiac Events, and Fatalities <content styleCode="italics">[see <linkHtml href="#LINK_3d045550-60a7-4a3c-b87a-7bfd32a84abc">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Cerebrovascular Adverse Reactions and Fatalities <content styleCode="italics">[see <linkHtml href="#LINK_e48c6a70-d2a3-4590-bc8d-402e7eec0511">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Other Vasospasm Related Adverse Reactions<content styleCode="italics"> [see <linkHtml href="#LINK_17df11b4-573c-4c7d-993d-6e6507ff5b6e">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Increase in Blood Pressure<content styleCode="italics"> [see <linkHtml href="#LINK_98a36d82-4475-4888-b9ab-5743f32c5ecb">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Medication Overuse Headache <content styleCode="italics">[see <linkHtml href="#LINK_1dc5aa46-7e3d-4a71-a274-ad3f63e16ac0">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Preterm Labor <content styleCode="italics">[see <linkHtml href="#LINK_8cf32adc-f355-4c72-8643-bc76dc860acc">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Fibrotic Complications<content styleCode="italics"> [see <linkHtml href="#LINK_709f64c1-1cf9-4482-85af-e3ea101bf09e">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity <content styleCode="italics">[see <linkHtml href="#LINK_ddda22cd-ca7b-4b7b-9a7e-2d01ba08a65c">Warnings and Precautions (5.9)</linkHtml>]</content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions associated with the use of dihydroergotamine were identified in clinical studies or postmarketing reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the drug exposure.</paragraph>
                  <paragraph>Serious cardiac events, including some that have been fatal, have occurred following use of dihydroergotamine. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation<content styleCode="italics"> [see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml> and <linkHtml href="#LINK_e48c6a70-d2a3-4590-bc8d-402e7eec0511">Warnings and Precautions (5.3)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>Fibrotic complications have been reported in association with long term use of injectable dihydroergotamine mesylate <content styleCode="italics">[see <linkHtml href="#LINK_709f64c1-1cf9-4482-85af-e3ea101bf09e">Warnings and Precautions (5.8)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>Vasospasm, paresthesia, hypertension, dizziness, anxiety, dyspnea, headache, flushing, diarrhea, rash, increased sweating, and pleural and retroperitoneal fibrosis occurred after long-term use of dihydroergotamine.</paragraph>
                  <paragraph>Cases of myocardial infarction and stroke have been reported following the use of dihydroergotamine <content styleCode="italics">[see <linkHtml href="#LINK_3d045550-60a7-4a3c-b87a-7bfd32a84abc">Warnings and Precautions (5.2)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Serious cardiac events (including fatal) that have been reported with dihydroergotamine mesylate injection use include coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, ventricular fibrillation. (<linkHtml href="#LINK_9440e503-baf7-441c-991f-439bc85d32c3">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at </content>
                           <content styleCode="bold">1-877-835-5472</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_502b69ea-bc62-44f2-99bf-3b1e2befd8e4">
               <id root="83fece61-3333-4c6f-ba9b-59701a710052"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20250515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Beta Blockers/Nicotine:</content> May potentiate/provoke vasoconstriction. (<linkHtml href="#LINK_abdb6751-3a7d-4300-a9fb-30ef40fb4ad6">7.3</linkHtml>, <linkHtml href="#LINK_d5e7b30e-71a6-42d7-ab30-9b66d5c5e7e7">7.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Selective Serotonin Reuptake Inhibitors: </content>Weakness, hyperreflexia, and incoordination may occur with coadministration. (<linkHtml href="#LINK_73d46ac9-675f-45b8-b6c2-2965576d1527">7.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_7cdd1f9c-de24-47c9-9252-d4e99fcf42cd">
                     <id root="3131d62c-a234-4c17-a4cb-d5d9316ad841"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 CYP3A4 Inhibitors</title>
                     <text>
                        <paragraph>There have been rare reports of serious adverse events in connection with the coadministration of intravenous administration of dihydroergotamine and strong CYP3A4 inhibitors resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities <content styleCode="italics">[see <linkHtml href="#LINK_d6d8105e-1465-4636-b4a9-6a7edd29450c">Warnings and Precautions (5.1)</linkHtml>].</content> The use of strong CYP3A4 inhibitors with BREKIYA is contraindicated <content styleCode="italics">[see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml>].</content> Administer moderate CYP3A4 inhibitors with caution.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c962e338-c452-4a01-b05c-84d272adbf9e">
                     <id root="7a48b7a5-88f7-4ac9-8fff-1c8eb3af979a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Triptans</title>
                     <text>
                        <paragraph>Triptans (serotonin [5-HT 1B/1D receptor agonists) have been reported to cause coronary artery vasospasm, and its effect could be additive with BREKIYA. Therefore, triptans and BREKIYA should not be taken within 24 hours of each other <content styleCode="italics">[see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_abdb6751-3a7d-4300-a9fb-30ef40fb4ad6">
                     <id root="bfc9fb6a-16e2-421e-bff2-bbe15652c0b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Beta Blockers</title>
                     <text>
                        <paragraph>There have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_39bc192e-2b0c-40b9-a40a-952a3527f240">
                     <id root="3d06ef6d-031c-414e-9684-bc1a4838822f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Vasoconstrictors</title>
                     <text>
                        <paragraph>BREKIYA is contraindicated for use with peripheral and central vasoconstrictors because the combination may cause synergistic elevation of blood pressure <content styleCode="italics">[see <linkHtml href="#LINK_98a36d82-4475-4888-b9ab-5743f32c5ecb">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d5e7b30e-71a6-42d7-ab30-9b66d5c5e7e7">
                     <id root="65cb4e0b-8a2e-439a-8a96-ab4c2d919944"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Nicotine</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy <content styleCode="italics">[see <linkHtml href="#LINK_3d045550-60a7-4a3c-b87a-7bfd32a84abc">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#LINK_17df11b4-573c-4c7d-993d-6e6507ff5b6e">5.4</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_73d46ac9-675f-45b8-b6c2-2965576d1527">
                     <id root="54d549fb-6c5a-4f63-8dd6-d7d9fa0b3fb2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6 Selective Serotonin Reuptake
Inhibitors</title>
                     <text>
                        <paragraph>Weakness, hyperreflexia, and incoordination have been reported rarely when 5-HT<sub>1</sub> agonists have been co-administered with selective serotonin reuptake inhibitors (SSRI’s) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline). </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d8fb27d1-edc0-46b8-9cc1-d87f6735066d">
               <id root="187f6419-fdea-45c8-b3ec-91b93dcafa25"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <br/>
               </text>
               <effectiveTime value="20250515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pregnancy: Based on animal data, may cause fetal harm. (<linkHtml href="#LINK_c7ddff79-330d-427b-b47b-400ef0464579">8.1</linkHtml>)</item>
                           <item>Lactation: Advise not to use during breastfeeding. (<linkHtml href="#LINK_b6a0645b-75e0-4d44-80e3-18b6b0e91f71">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_c7ddff79-330d-427b-b47b-400ef0464579">
                     <id root="d472fe27-4604-478f-b23f-abd09f85ac04"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data from published literature indicate an increased risk of preterm delivery with dihydroergotamine, the active moiety in BREKIYA, use during pregnancy. Avoid use of BREKIYA during pregnancy <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_ddda22cd-ca7b-4b7b-9a7e-2d01ba08a65c">Warnings and Precautions (5.9)</linkHtml>]</content>. Data collected over decades have shown no increased risk of major birth defects or miscarriage with the use of dihydroergotamine mesylate during pregnancy<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>In animal reproduction studies, adverse effects on development were observed following administration of dihydroergotamine mesylate during pregnancy (decreased fetal body weight and/or skeletal ossification) in rats and rabbits or during pregnancy and lactation in rats (decreased body weight and impaired reproductive function in the offspring) at doses that were not associated with maternal toxicity <content styleCode="italics">(see Data).</content>
                        </paragraph>
                        <paragraph>The estimated rate of major birth defects (2.2% to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk </content>
                        </paragraph>
                        <paragraph>Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Intranasal administration of dihydroergotamine mesylate to pregnant rats throughout the period of organogenesis resulted in decreased fetal body weight and/or skeletal ossification at doses of 0.16 mg/day or greater. A no-effect level for adverse effects on embryofetal toxicity was not identified in rats. Intranasal administration of dihydroergotamine mesylate to pregnant rabbits throughout organogenesis resulted in decreased skeletal ossification at 3.6 mg/day. The no-effect dose for adverse effects on embryofetal toxicity in rabbits was 1.2 mg/day. </paragraph>
                        <paragraph>Intranasal administration of dihydroergotamine mesylate to female rats throughout pregnancy and lactation resulted in decreased body weight and impaired reproductive function (decreased mating indices) in the offspring at doses of 0.16 mg/day or greater. A no-effect dose for adverse developmental effects in rats was not established. Effects on offspring development occurred at doses below those that produced evidence of maternal toxicity in these studies.</paragraph>
                        <paragraph>Dihydroergotamine-induced intrauterine growth retardation has been attributed to reduced uteroplacental blood flow resulting from prolonged vasoconstriction of the uterine vessels and/or increased myometrial tone.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b6a0645b-75e0-4d44-80e3-18b6b0e91f71">
                     <id root="2a356e63-d18f-4043-9dec-c0caef360c32"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There are no data on the presence of dihydroergotamine in human milk; however, ergotamine, a related drug, is excreted in human milk. There are reports of vomiting, diarrhea, weak pulse, and unstable blood pressure in breastfed infants exposed to ergotamine. BREKIYA may reduce milk supply because it may decrease prolactin levels.</paragraph>
                        <paragraph>Because of the potential for reduced milk supply and serious adverse events in the breastfed infant, including diarrhea, vomiting, weak pulse, and unstable blood pressure; advise patients not to breastfeed during treatment with BREKIYA and for 3 days after the last dose. Breast milk supply during this time should be pumped and discarded.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2a76746e-04aa-4ca6-8470-1aa0e68d79ac">
                     <id root="3c78e679-1cfb-4e97-b540-7fb287bcb927"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cfdda6aa-7532-4270-96d5-af486ee9fadd">
                     <id root="08b80a83-b1eb-4908-9564-b8acd9779815"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of dihydroergotamine products did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f361ce03-b550-4573-9559-10a914dc710b">
               <id root="ec5b265e-faa5-4811-a8f4-07554f884b58"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <text/>
               <effectiveTime value="20250515"/>
               <component>
                  <section ID="LINK_b3be8d1e-e347-45ef-81b5-3ea69ae3f89c">
                     <id root="e3bf4969-a101-4b16-83fa-65b285a7a5b4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>BREKIYA contains dihydroergotamine (as the mesylate salt), which is not a controlled substance. </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9d514b8a-c482-4df8-bbcc-3b1abfebfb35">
                     <id root="2f22f093-fb58-4aec-8957-e2bc0720ec7b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Currently available data have not demonstrated drug abuse with dihydroergotamine. However, cases of drug abuse in patients on other forms of ergot therapy have been reported.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_619940da-8cc8-49fa-97c5-716bf8486ef9">
                     <id root="1ad707b6-0247-431a-9f24-33a7505c230a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Currently available data have not demonstrated physical or psychological dependence with dihydroergotamine. However, cases of psychological dependence in patients on other forms of ergot therapy have been reported.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_7672321b-456b-49d1-95e6-3b804a643ebe">
               <id root="2d58ab77-b52f-4c97-bec0-2842b05701ae"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Symptoms</content>
                  </paragraph>
                  <paragraph>Excessive doses of dihydroergotamine may result in peripheral signs and symptoms of ergotism. </paragraph>
                  <paragraph>In general, the symptoms of an acute BREKIYA overdose may be similar to those of an ergotamine overdose, although there may be less pronounced nausea and vomiting with BREKIYA. The symptoms of an ergotamine overdose include the following: numbness, tingling, pain, and cyanosis of the extremities associated with diminished or absent peripheral pulses; respiratory depression; an increase and/or decrease in blood pressure, usually in that order; confusion, delirium, convulsions, and coma; and/or some degree of nausea, vomiting, and abdominal pain.</paragraph>
                  <paragraph>In laboratory animals, dihydroergotamine was lethal when given at intravenous doses of 44 mg/kg in mice, 130 mg/kg in rats, and 37 mg/kg in rabbits.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Treatment</content>
                  </paragraph>
                  <paragraph>Treatment includes discontinuance of the drug, local application of warmth to the affected area, the administration of vasodilators, and nursing care to prevent tissue damage. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20250515"/>
            </section>
         </component>
         <component>
            <section ID="LINK_94dfdaa6-3893-42c2-9260-ca4a11462f2f">
               <id root="5a939097-977d-40b4-b25f-066c3ea2dbeb"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>BREKIYA (dihydroergotamine mesylate) injection is an ergotamine derivative. Dihydroergotamine mesylate is a white or almost white, crystalline powder. It is slightly soluble in water and chloroform and sparingly soluble in methanol. The chemical name for dihydroergotamine mesylate is ergotaman-3´,6´,18-trione,9,10-dihydro-12´-hydroxy-2´-methyl-5´-(phenylmethyl) monomethanesulfonate (salt). Its molecular weight is 679.8g/mol and its molecular formula is C<sub>33</sub>H<sub>37</sub>N<sub>5</sub>O<sub>5</sub>∙CH<sub>4</sub>O<sub>3</sub>S.</paragraph>
                  <paragraph>The chemical structure is</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>BREKIYA is a clear, colorless, sterile solution supplied in 1 mL single-dose autoinjector for subcutaneous administration. Each mL contains 1 mg dihydroergotamine mesylate, USP (equivalent to 0.86 mg of dihydroergotamine). BREKIYA also contains ethanol, USP 6.1% by volume; glycerin, USP 15% by weight; water for injection, USP; may contain methanesulfonic acid and/or sodium hydroxide, NF for pH adjustment. pH range is 3.4 to 4.9.</paragraph>
               </text>
               <effectiveTime value="20250515"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bccb04cc-3991-4ea2-b6f4-04a6afd0b8f3">
               <id root="3985bffa-1837-45d8-9334-3266c7a60d51"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250515"/>
               <component>
                  <section ID="LINK_f1abae1d-7871-43d7-bbb1-77ffe4b1ffb5">
                     <id root="a4915972-603e-4e37-8b93-e41c671ffd77"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Dihydroergotamine binds with high affinity to 5-HT<sub>1Dα</sub> and 5-HT<sub>1Dβ</sub> receptors.  The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT<sub>1D</sub> receptors.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_341097fb-f403-4324-b506-0e5f01fc8f3a">
                     <id root="a2fff391-c918-4623-9e1e-dd0a9478074f"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Significant elevation in blood pressure has been reported in patients treated with dihydroergotamine with and without a history of hypertension <content styleCode="italics">[see <linkHtml href="#LINK_98a36d82-4475-4888-b9ab-5743f32c5ecb">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Dihydroergotamine possesses oxytocic properties <content styleCode="italics">[see <linkHtml href="#LINK_8cf32adc-f355-4c72-8643-bc76dc860acc">Warnings and Precautions (5.7)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_40da22ab-9880-419c-aac4-3222230c217b">
                     <id root="64c2dcfb-4967-4f27-9526-9f551be05ae4"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Following BREKIYA administration, the mean maximum plasma concentration was 3.8 ng/mL, and the median time from dosing to maximum plasma concentration was approximately 0.4 hours. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Dihydroergotamine mesylate is 93% plasma protein bound. The apparent steady-state volume of distribution is approximately 800 liters.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Four dihydroergotamine mesylate metabolites have been identified in human plasma following oral administration. The major metabolite, 8´-β-hydroxydihydroergotamine, exhibits affinity equivalent to its parent for adrenergic and 5-HT receptors and demonstrates equivalent potency in several venoconstrictor activity models, <content styleCode="italics">in vivo</content> and <content styleCode="italics">in vitro</content>. The other metabolites (i.e., dihydrolysergic acid, dihydrolysergic amide, and a metabolite formed by oxidative opening of the proline ring) are of minor importance. Following nasal administration, total metabolites represent only 20% to 30% of plasma AUC. Quantitative pharmacokinetic characterization of the four metabolites has not been performed.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>The major excretory route of dihydroergotamine is via the bile in the feces. The total body clearance is 1.5 L/min which reflects mainly hepatic clearance. Only 6% to 7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection. The renal clearance (0.1 L/min) is unaffected by the route of dihydroergotamine administration. The decline of plasma dihydroergotamine after intramuscular or intravenous administration is multi-exponential with a terminal half-life of about 9 hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No studies have been conducted on the effect of renal or hepatic impairment, gender, race, or ethnicity on dihydroergotamine pharmacokinetics <content styleCode="italics">[see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>Pharmacokinetic interactions have been reported in patients treated orally with other ergot alkaloids (e.g., increased levels of ergotamine) and macrolide antibiotics, presumably due to inhibition of cytochrome P450 3A metabolism of the alkaloids. Dihydroergotamine has also been shown to be an inhibitor of cytochrome P450 3A catalyzed reactions and rare reports of ergotism have been obtained from patients treated with dihydroergotamine and macrolide antibiotics (e.g., clarithromycin, erythromycin), and in patients treated with dihydroergotamine and protease inhibitors (e.g., ritonavir), presumably due to inhibition of cytochrome P450 3A metabolism of ergotamine <content styleCode="italics">[see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5daa79e6-a212-4003-bec5-c4661f04ac51">
               <id root="49d66447-cd93-425e-9d5b-d1f83bb18911"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250515"/>
               <component>
                  <section ID="LINK_de7b6a6c-102a-443a-8563-e9fb72cae2d9">
                     <id root="6d5c2f35-a9ea-499a-9fc2-65f3fbef3d84"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis,
Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>In a 2-year mouse carcinogenicity study, subcutaneous (SC) administration of dihydroergotamine mesylate (0, 0.5, 1.5 or 5 mg/kg/day) resulted in an increased incidence of fibrosarcoma at the injection sites in males and females at the high dose. The higher dose not associated with an increase in tumors (1.5 mg/kg/day) is approximately 2 times the recommended human dose (RHD) of 3 mg/day SC on a body surface area (mg/m<sup>2</sup>) basis.</paragraph>
                        <paragraph>In a 2-year rat carcinogenicity study, intranasal administration of dihydroergotamine mesylate (0, 0.4, 0.8 or 1.6 mg/day for 13 weeks, followed by 0, 0.08, 0.24 or 0.8 mg/day for the remainder of the study) did not result in an increase in tumors.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Dihydroergotamine mesylate was negative in an in vitro mutagenicity (Ames) assay and positive in in vitro chromosomal aberration (V79 Chinese hamster cell assay with metabolic activation, and human peripheral blood lymphocyte) assays. Dihydroergotamine was negative in <content styleCode="italics">in vivo</content> micronucleus assays in mouse and hamster.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Intranasal administration of dihydroergotamine to rats at doses up to 1.6 mg/day was not associated with adverse effects on fertility.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a0b45d85-af35-4ea1-b85b-0827eb4c813b">
               <id root="61213b93-6697-41ca-8526-9a58aa706823"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text/>
               <effectiveTime value="20250515"/>
               <component>
                  <section ID="LINK_bab34c7b-2809-4e1c-b8cc-a4912060b90e">
                     <id root="c90c6876-6e80-40eb-a9f0-570f285643f8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>BREKIYA (dihydroergotamine mesylate) injection is a clear, colorless, sterile solution of 1 mg/mL dihydroergotamine mesylate available as:</paragraph>
                        <table width="100%">
                           <col width="17px"/>
                           <col width="17px"/>
                           <col width="17px"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Dosage Unit</content> </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Package Size</content> </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">NDC #</content> </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">1 mL prefilled single-dose autoinjector </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Carton of 4 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">NDC 64896-509-02 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Caution: </content>The rigid needle shield of the BREKIYA autoinjector contains a needle cover (located inside the cap) that contains dry natural rubber, which is made from latex <content styleCode="italics">[see <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</linkHtml> </content>and <content styleCode="italics">
                              <content styleCode="italics">
                                 <content styleCode="italics">
                                    <linkHtml href="#LINK_ddda22cd-ca7b-4b7b-9a7e-2d01ba08a65c">Warnings and Precautions </linkHtml>
                                 </content>
                                 <content styleCode="italics">
                                    <linkHtml href="#LINK_ddda22cd-ca7b-4b7b-9a7e-2d01ba08a65c">(5.9)</linkHtml>
                                 </content>
                              </content>].</content>
                        </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_817643b2-90ae-45b5-8082-c77cc8505d7e">
                     <id root="411372ae-07a7-4eea-8262-8b137f6d7b2c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.2 Storage
and Handling</title>
                     <text>
                        <paragraph>Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP controlled room temperature]. Do not refrigerate or freeze. Protect from light. Retain in original pack until time of use.</paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_7f1499bb-6eb0-433e-ad99-1e4cdeab02da">
               <id root="f0b4a3d1-0465-4f35-8ec0-710b1ee4aec1"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT
COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Serious and/or Life-Threatening Reactions with Coadministration of CYP3A4 Inhibitors</content>
                  </paragraph>
                  <paragraph>Inform patients that serious and/or life-threatening peripheral ischemia (cerebral ischemia and/or ischemia of the extremities) has been associated with the coadministration of dihydroergotamine and strong CYP3A4 inhibitors, <content styleCode="italics">[see <content styleCode="italics">
                           <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">)</linkHtml>
                        </content>, <content styleCode="italics">
                           <linkHtml href="#LINK_d6d8105e-1465-4636-b4a9-6a7edd29450c">Warnings and Precautions (</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_d6d8105e-1465-4636-b4a9-6a7edd29450c">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_d6d8105e-1465-4636-b4a9-6a7edd29450c">)</linkHtml>
                        </content>, and <content styleCode="italics">
                           <linkHtml href="#LINK_7cdd1f9c-de24-47c9-9252-d4e99fcf42cd">Drug Interactions (</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_7cdd1f9c-de24-47c9-9252-d4e99fcf42cd">7.1</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_7cdd1f9c-de24-47c9-9252-d4e99fcf42cd">)</linkHtml>
                        </content>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Myocardial Ischemia and/or Infarction, Other Cardiac Events, Cerebrovascular Events, and Fatalities</content>
                  </paragraph>
                  <paragraph>Inform patients of the risk for serious cardiac, cerebrovascular, and other vasospasm related events. Advise patients to notify their healthcare provider if they develop any risk factors or symptoms while taking BREKIYA. Inform patients that nicotine may provoke vasoconstriction predisposing to a greater ischemic response <content styleCode="italics">[see <content styleCode="italics">
                           <linkHtml href="#LINK_3d045550-60a7-4a3c-b87a-7bfd32a84abc">Warnings and Precautions (</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_3d045550-60a7-4a3c-b87a-7bfd32a84abc">5.2</linkHtml>
                        </content>
                     </content>
                     <content styleCode="italics">, </content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_e48c6a70-d2a3-4590-bc8d-402e7eec0511">5.3</linkHtml>
                     </content>
                     <content styleCode="italics">, </content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_17df11b4-573c-4c7d-993d-6e6507ff5b6e">5.4</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Increase in Blood Pressure</content>
                  </paragraph>
                  <paragraph>Inform patients of the risk for significant elevation in blood pressure <content styleCode="italics">[see <linkHtml href="#LINK_98a36d82-4475-4888-b9ab-5743f32c5ecb">Warnings and Precautions (5.5)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Medication Overuse Headache </content>
                  </paragraph>
                  <paragraph>Inform patients that use of drugs to treat migraine attacks for 10 or more days per month may lead to an exacerbation of headache, and encourage patients to record headache frequency and drug use (e.g., by keeping a headache diary) <content styleCode="italics">[see <content styleCode="italics">
                           <linkHtml href="#LINK_1dc5aa46-7e3d-4a71-a274-ad3f63e16ac0">Warnings and Precautions (</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_1dc5aa46-7e3d-4a71-a274-ad3f63e16ac0">5.6</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_1dc5aa46-7e3d-4a71-a274-ad3f63e16ac0">)</linkHtml>
                        </content>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity</content>
                  </paragraph>
                  <paragraph>Inform patients that the rigid needle shield of the BREKIYA autoinjector contains a needle cover (located inside the cap) that contains dry natural rubber, which is made from latex, and can cause allergic reactions in latex-sensitive individuals <content styleCode="italics">[see <linkHtml href="#LINK_ddda22cd-ca7b-4b7b-9a7e-2d01ba08a65c">Warnings and Precautions (5.9)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Advise patients to inform their healthcare providers if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions <content styleCode="italics">[see <content styleCode="italics">
                           <linkHtml href="#LINK_502b69ea-bc62-44f2-99bf-3b1e2befd8e4">Drug Interactions (</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_502b69ea-bc62-44f2-99bf-3b1e2befd8e4">7</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_502b69ea-bc62-44f2-99bf-3b1e2befd8e4">)</linkHtml>
                        </content>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy </content>
                  </paragraph>
                  <paragraph>Advise patients of the risk for preterm birth. Advise women to inform their healthcare provider if they are pregnant or intend to become pregnant <content styleCode="italics">[see <content styleCode="italics">
                           <linkHtml href="#LINK_8cf32adc-f355-4c72-8643-bc76dc860acc">Warnings and Precautions (</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_8cf32adc-f355-4c72-8643-bc76dc860acc">5.7</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_8cf32adc-f355-4c72-8643-bc76dc860acc">)</linkHtml>
                        </content>, <content styleCode="italics">
                           <linkHtml href="#LINK_c7ddff79-330d-427b-b47b-400ef0464579">Use in Specific Populations (</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_c7ddff79-330d-427b-b47b-400ef0464579">8.1</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_c7ddff79-330d-427b-b47b-400ef0464579">)</linkHtml>
                        </content>]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation </content>
                  </paragraph>
                  <paragraph>Advise patients not to breastfeed during treatment with BREKIYA <content styleCode="italics">[</content>
                     <content styleCode="italics">see </content>
                     <content styleCode="italics">
                        <content styleCode="italics">
                           <linkHtml href="#LINK_b6a0645b-75e0-4d44-80e3-18b6b0e91f71">Use in Specific Populations (</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_b6a0645b-75e0-4d44-80e3-18b6b0e91f71">8.2</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_b6a0645b-75e0-4d44-80e3-18b6b0e91f71">)</linkHtml>
                        </content>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Important Administration Instructions</content>
                  </paragraph>
                  <paragraph>Advise patients on the proper use of BREKIYA prior to the initial use and instruct them to read the Instructions for Use <content styleCode="italics">[see <linkHtml href="#LINK_d109a581-1854-4803-8a3c-31578bb26380">Dosage and Administration (2.3)</linkHtml>]</content>
                     <content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>For more information, call 1-877-835-5472.</paragraph>
                  <paragraph>BREKIYA<sup>®</sup> is a registered trademark of Amneal Pharmaceuticals LLC.</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal Specialty, a division of Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <paragraph>Bridgewater, NJ  08807</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal Pharmaceuticals Pvt. Ltd.</content>
                  </paragraph>
                  <paragraph> Ahmedabad 382213, INDIA</paragraph>
                  <paragraph>Rev. 05-2025-01</paragraph>
               </text>
               <effectiveTime value="20250515"/>
            </section>
         </component>
         <component>
            <section ID="LINK_b86e0899-49f6-4e94-a308-39430f2be4d5">
               <id root="1b5681cb-04b5-4396-b4bb-47edc39cd38c"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>MEDICATION GUIDE</title>
               <text>
                  <table width="100%">
                     <col width="17px"/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">BREKIYA<sup>®</sup>
                                 </content>
                                 <content styleCode="bold">[breh-kee-yah]</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                                 <content styleCode="bold">(dihydroergotamine mesylate)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                                 <content styleCode="bold">injection, for subcutaneous use</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about BREKIYA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">BREKIYA can cause serious side effects, including: </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Serious problems with blood circulation to your legs and feet (peripheral ischemia)</content>. BREKIYA can cause peripheral ischemia when you take it with certain medicines known as CYP3A4 inhibitors. Peripheral ischemia may lead to a stroke and death. Stop taking BREKIYA and get emergency medical help right away if you have any of the following symptoms:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>cramping and pain in your legs or hips</item>
                                 <item>feeling of heaviness or tightness in your leg muscles</item>
                                 <item>burning or aching pain in your feet or toes while resting</item>
                                 <item>numbness, tingling, or weakness in your legs</item>
                                 <item>cold feeling or color changes in 1 or both legs or feet</item>
                                 <item>slurred speech</item>
                                 <item>sudden weakness</item>
                              </list>
                              <paragraph>Do not take medicines known as strong CYP3A4 inhibitors, such as:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item> ritonavir </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>indinavir </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>clarithromycin </item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>itraconazole </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>nelfinavir </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>erythromycin </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>ketoconazole </item>
                              </list>
                           </td>
                           <td styleCode=" Rrule"> </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Lrule Rrule">These are not all of the medicines that could affect how BREKIYA works. Your healthcare provider can tell you if it is safe to take BREKIYA with other medicines. </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is BREKIYA?</content>
                              </paragraph>
                              <paragraph>BREKIYA is a prescription medicine used for the acute treatment of migraine with or without aura and acute cluster headaches in adults.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>BREKIYA is not used to prevent migraine.</item>
                                 <item>BREKIYA is not used to treat other types of headaches such as hemiplegic migraines (that make you unable to move on one side of your body) or basilar migraines (rare form of migraine with aura).</item>
                              </list>
            It is not known if BREKIYA is safe and effective in children. </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Who should not take BREKIYA? Do not use BREKIYA if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are taking medicines known as strong CYP3A4 inhibitors.</item>
                                 <item>have heart problems or a history of heart problems.</item>
                                 <item>have uncontrolled high blood pressure.</item>
                                 <item>have narrowing of blood vessels in your legs, arms, stomach, or kidneys (peripheral vascular disease).</item>
                                 <item>have sepsis.</item>
                                 <item>have had vascular surgery.</item>
                                 <item>have severe liver problems.</item>
                                 <item>have severe kidney problems.</item>
                                 <item>are allergic to dihydroergotamine, ergot alkaloids, latex, or any of the ingredients in BREKIYA. See the end of this Medication Guide for a complete list of ingredients in BREKIYA.</item>
                                 <item>have taken any of the following medicines in the last 24 hours: </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>sumatriptan </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>almotriptan </item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>eletriptan </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>frovatriptan </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>naratriptan </item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>rizatriptan </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>ergotamine or ergotamine-type medicines </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>zolmitriptan </item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule"> </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>have taken any medicines that constrict your blood vessels or raise your blood pressure. </item>
                              </list>
                              <paragraph>Ask your healthcare provider if you are not sure if you are taking any of these medicines. Your healthcare provider can tell you if it is safe to take BREKIYA with other medicines. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before you take BREKIYA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have high blood pressure.</item>
                                 <item>have liver problems.</item>
                                 <item>have kidney problems.</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have risk factors for heart disease. You have a higher risk for heart disease if you:
                <list listType="unordered" styleCode="Circle">
                                       <item>have high blood pressure</item>
                                       <item>have high cholesterol levels</item>
                                       <item>smoke</item>
                                       <item>are overweight</item>
                                       <item>have diabetes</item>
                                       <item>have a family history of heart disease</item>
                                    </list>
                                 </item>
                                 <item>are taking medicines known as strong CYP3A4 inhibitors.</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are pregnant or plan to become pregnant. BREKIYA may cause preterm labor. BREKIYA should be avoided during pregnancy. Talk to your healthcare provider right away if you are pregnant or want to become pregnant. </item>
                                 <item>are breastfeeding or plan to breastfeed. BREKIYA may reduce breast milk supply and pass into your breast milk. BREKIYA may be harmful to your baby. Do not breastfeed your baby while taking BREKIYA and for 3 days after you use BREKIYA. Talk with your healthcare provider about the best way to feed your baby if you take BREKIYA.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your healthcare provider will decide if you can take BREKIYA with your other medicines.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your healthcare provider if you take:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>sumatriptan </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>fluconazole </item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>propranolol or other medicines that can lower your heart rate </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>ergot-type medicine </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>grapefruit juice </item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>any medicines that can increase your blood pressure </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>saquinavir </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>zileuton </item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>selective serotonin reuptake inhibitors </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>nefazodone </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>nicotine </item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule"> </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Lrule Rrule">These are not all of the medicines that could affect how BREKIYA works. Your healthcare provider can tell you if it is safe to take BREKIYA with other medicines. </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I use BREKIYA? </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>Certain people should take their first dose of BREKIYA in their healthcare provider’s office or in another medical setting. Ask your healthcare provider if you should take your first dose in a medical setting.</item>
                                 <item>BREKIYA is for injection under the skin (subcutaneous) only.</item>
                                 <item>Use BREKIYA exactly as your healthcare provider tells you to use it. </item>
                                 <item>See the detailed Instructions for Use that comes with BREKIYA for information about how to use BREKIYA. </item>
                                 <item>Each autoinjector contains 1 dose (1 mg) of BREKIYA. </item>
                                 <item>If your headache comes back after the first complete dose, you may give yourself up to 2 more doses as needed. Wait at least 1 hour between doses.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject more than 3 doses (3 mg) of BREKIYA in a 24-hour period or 6 doses (6 mg) in a 1-week (7 day) period. </item>
                                 <item>Using BREKIYA for 10 or more days in 1 month may make your headache worse. You should write down when you have headaches and when you take BREKIYA so that you can talk with your healthcare provider about how BREKIYA is working for you.</item>
                                 <item>If you use too much BREKIYA, call your healthcare provider or the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of </content>
                                 <content styleCode="bold">BREKIYA</content>
                                 <content styleCode="bold">?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">BREKIYA can cause serious side effects, including: </content>
                              </paragraph>
                              <paragraph>See<content styleCode="bold"> “What is the most important information I should know about BREKIYA?”</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Heart attack and other heart problems. </content>Heart problems may lead to death. Stop taking BREKIYA and get emergency medical help right away if you have any of the following symptoms of a heart attack:
                <list listType="unordered" styleCode="Circle">
                                       <item>discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back</item>
                                       <item>severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw</item>
                                       <item>pain or discomfort in your arms, back, neck, jaw, or stomach</item>
                                       <item>shortness of breath with or without chest discomfort</item>
                                       <item>breaking out in a cold sweat</item>
                                       <item>nausea or vomiting</item>
                                       <item>feeling lightheaded</item>
                                    </list>
                                    <paragraph> BREKIYA is not for people with risk factors for heart disease unless a heart exam is done and shows no problem. See <content styleCode="bold">“Before you take BREKIYA, tell your healthcare provider about all of your medical conditions, including if you:” </content>for the risk factors for heart disease.</paragraph>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Stroke. </content>Stop using BREKIYA and get emergency medical help right away if you have any of the following symptoms of a stroke:</item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>face drooping</item>
                                 <item>unusual weakness or numbness</item>
                                 <item>slurred speech</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Changes in color or sensation in your fingers and toes (Raynaud’s syndrome).</content>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Stomach and intestinal problems</content> (gastrointestinal and colonic ischemic events). Symptoms of gastrointestinal and colonic ischemic events include: </item>
                              </list>
             </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>sudden or severe stomach pain </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>constipation or diarrhea </item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>stomach pain after meals </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>bloody diarrhea </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>weight loss </item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>fever </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>nausea or vomiting </item>
                              </list>
                           </td>
                           <td> </td>
                           <td colspan="2" styleCode=" Rrule"> </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Increased blood pressure.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Medicine overuse headache. </content>Some people who use too much BREKIYA may make their headaches worse (medicine overuse headache). If your headaches get worse, your healthcare provider may decide to stop your treatment with BREKIYA.</item>
                                 <item>
                                    <content styleCode="bold">Preterm labor.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Tissue changes (fibrotic complications).</content> Inflammation and fiber-like tissue that is not normal (fibrosis) can occur around the lungs and stomach.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common but serious side effects of BREKIYA are heart problems that happen but may lead to death. These heart problems include:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Circle">
                                 <item>temporary squeezing of arteries that supply the heart (coronary artery vasospasm)</item>
                                 <item>temporary decrease of blood flow to the heart (transient myocardial ischemia)</item>
                                 <item>heart rhythm problems (ventricular tachycardia and ventricular fibrillation)</item>
                              </list>
                              <paragraph>Symptoms of these heart problems include:</paragraph>
                              <paragraph>See “<content styleCode="bold">heart attack and other heart problems</content>.”</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>numbness or tingling in your fingers and toes.</item>
                                 <item>muscle pain or cramps in your arms and legs.</item>
                                 <item>weakness in your legs.</item>
                                 <item>temporary speeding or slowing of your heart rate.</item>
                                 <item>swelling or itching.</item>
                              </list>
                              <paragraph>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of BREKIYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store </content>
                                 <content styleCode="bold">BREKIYA</content>
                                 <content styleCode="bold">?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store BREKIYA at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>Do not refrigerate or freeze BREKIYA. </item>
                                 <item>Protect BREKIYA from light. </item>
                                 <item>Keep BREKIYA in the original pack until ready to use.</item>
                              </list>
                              <content styleCode="bold">Keep </content>
                              <content styleCode="bold">BREKIYA </content>
                              <content styleCode="bold">and all medicines out of the reach of children. </content> </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of </content>
                                 <content styleCode="bold">BREKIYA</content>
                                 <content styleCode="bold">. </content>
                              </paragraph>
            Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BREKIYA for a condition for which it was not prescribed. Do not give BREKIYA to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about BREKIYA that is written for health professionals. </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in </content>
                                 <content styleCode="bold">BREKIYA</content>
                                 <content styleCode="bold">? </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content> dihydroergotamine mesylate, USP </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> ethanol, glycerin, water for injection, methanesulfonic acid or sodium hydroxide.<br/>
                                 <br/>
            Distributed by:</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Amneal Specialty, a division of Amneal Pharmaceuticals LLC</content>
                              </paragraph>
                              <paragraph>Bridgewater, NJ  08807<br/>
                                 <br/>Manufactured by:</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Amneal Pharmaceuticals Pvt. Ltd.</content>
                              </paragraph>
                              <paragraph>Ahmedabad 382213, INDIA<br/>
                                 <br/>
                                 <content styleCode="bold">For more information </content>
                                 <content styleCode="bold">or to report side-effects, call 1-877-835-5472.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <br/>
                                 </content>Rev. 05-2025-00</paragraph>
             </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration                                                                                                                          Issued: 05/2025</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250515"/>
            </section>
         </component>
         <component>
            <section ID="LINK_6f4725af-038b-419c-adad-3a696973e7f3">
               <id root="e554f773-89f4-48cc-ada1-0b7971937e4d"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>INSTRUCTIONS FOR USE</title>
               <text>
                  <table width="100%">
                     <col width="17px"/>
                     <col width="17px"/>
                     <tbody>
                        <tr>
                           <td styleCode=" Toprule Lrule">
                              <renderMultiMedia referencedObject="MM2"/> </td>
                           <td styleCode=" Toprule Rrule">
                              <renderMultiMedia referencedObject="MM3"/> </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <paragraph>This Instructions for Use contains information on how to inject BREKIYA.</paragraph>
            If there are any questions concerning the use of BREKIYA autoinjector, ask your healthcare provider, pharmacist or visit www.brekiya.com. </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Important Information You Need to Know Before Injecting BREKIYA</content> </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Warnings</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Circle">
                                 <item>BREKIYA is for injection under the skin (subcutaneous) only.</item>
                                 <item>The rigid needle shield of the BREKIYA autoinjector contains a needle cover (located inside the cap) that contains dry natural rubber, which is made from latex. Tell your healthcare provider if you are allergic to latex. </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> remove the red needle cap until you are ready to inject BREKIYA. Inject BREKIYA right away after removing the red needle cap. </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject BREKIYA if the autoinjector appears damaged, if the expiration date has passed, if the liquid medicine is cloudy, discolored or has floating flakes or particles. </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> throw away (dispose of) the autoinjector into the household trash. Throw away (dispose of) the autoinjector into a FDA-cleared sharps disposal container. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Dosing</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Circle">
                                 <item>Follow your healthcare provider’s dosing instructions for how often to inject BREKIYA autoinjector.
                </item>
                                 <item>Each autoinjector contains 1 dose (1 mg) of BREKIYA. After your first dose of BREKIYA, you may give yourself 2 more doses (for a total of 3 mg) as needed. Wait at least 1 hour between doses.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject more than 3 doses (3 mg) of BREKIYA in 1 day (24-hour) period.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject more than 6 doses (6 mg) during a 1-week (7-day) period. </item>
                              </list>
             </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Storing BREKIYA Autoinjector</content> </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>Store the BREKIYA autoinjector at room temperature between 68°F to 77°F (20°C to 25°C). </item>
                                 <item>Protect BREKIYA from light.</item>
                                 <item>Keep BREKIYA in the carton until ready to use. </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> refrigerate or freeze BREKIYA.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep BREKIYA and all medicines out of the reach of children.  </content> </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Autoinjector Parts</content> </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>This autoinjector is a prefilled single dose (1 time use), disposable device that gives a 1 mg subcutaneous (under the skin) injection of BREKIYA. Figure A shows a new and used autoinjector.</paragraph>
                              <renderMultiMedia referencedObject="MM4"/>
                              <renderMultiMedia referencedObject="MM5"/>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure A</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Preparing to Inject BREKIYA </content> </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Step 1: Wash Hands and Gather Supplies</content> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">1.1</content> Before you begin, wash your hands with soap and water (See Figure B). </paragraph>
             </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM6"/>
                              <paragraph>
                                 <content styleCode="bold">Figure B</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">1.2</content> Gather the following supplies (See Figure C): </paragraph>
                              <list listType="unordered" styleCode="Circle">
                                 <item>BREKIYA autoinjector foil pouch (inside carton)</item>
                                 <item>Alcohol swab</item>
                                 <item>Cotton balls or gauze</item>
                                 <item>Sharps container [See “Throwing Away (Disposing of) BREKIYA”]</item>
                              </list>
             </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">
                                    <renderMultiMedia referencedObject="MM7"/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure C</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Step 2: Remove and Inspect the Autoinjector</content> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">2.1</content> Tear open the foil pouch from the notch to remove the autoinjector (See Figure D). </paragraph>
             </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM8"/>
                              <paragraph>
                                 <content styleCode="bold">Figure D</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <paragraph>
                                 <content styleCode="bold">2.2</content> Check the expiration date printed on the autoinjector (See Figure E). Do not use the autoinjector if the expiration date has passed.
            </paragraph>
                              <paragraph>
                                 <content styleCode="bold">2.3</content> Check the liquid medicine in BREKIYA by looking through the viewing window (See Figure E). The liquid medicine in BREKIYA should be clear and colorless. It is normal to see one or more air bubbles.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not </content>inject if the liquid medicine appears cloudy, discolored, or has floating flakes or particles. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not </content>inject if the autoinjector appears to be damaged or broken. </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM9"/>
                              <paragraph>
                                 <content styleCode="bold">Figure E</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Step 3: Select and Prepare Injection Site</content> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">3.1</content> Locate your injection site. BREKIYA autoinjector should be injected into the skin in the middle of your thigh (See Figure F). </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> inject into moles, scars, birthmarks, or areas where the skin is tender, bruised, red, or hard. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not </content>inject through clothing. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not </content>inject into the same spot 2 times in a row. </paragraph>
                              <content styleCode="bold">Important:</content> This injection should be at least 2 inches away from the last injection site.  </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM10"/>
                              <paragraph>
                                 <content styleCode="bold">Figure F</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">3.2</content> Clean the injection site with an alcohol swab (See Figure G). </paragraph>
                              <paragraph>Wait for the injection site to air dry before giving the injection. Do not touch the clean injection site again before you inject BREKIYA.</paragraph>
             </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM11"/>
                              <paragraph>
                                 <content styleCode="bold">Figure G</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Injecting BREKIYA </content> </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Step 4: Remove Red Needle Cap and Position the Autoinjector</content> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">4.1</content> Remove the red needle cap by pulling it straight off (See Figure H) and throw it away in the household trash. </paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not </content>bend or twist the cap while removing. </paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not </content>touch the white safety guard after the red needle cap is removed. </paragraph>
             </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM12"/>
                              <paragraph>
                                 <content styleCode="bold">Figure H</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">4.2</content> Position the autoinjector straight onto the cleaned injection site with the white safety guard resting on the skin (See Figure I). </paragraph>
             </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">
                                    <renderMultiMedia referencedObject="MM13"/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure I</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Step 5: Give Injection</content> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">5.1</content> Push the autoinjector down against the skin until you do not see the white safety guard (See Figure J). </paragraph>
                              <content styleCode="bold">Important:</content> Keep downward pressure on the skin throughout the injection process. <content styleCode="italics"> </content> </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM14"/>
                              <paragraph>
                                 <content styleCode="bold">Figure J</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">5.2</content> Press and release the gray activation button to start the injection (See Figure K). You will hear a “click” sound when the injection starts. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Be Patient. Do not </content>lift the autoinjector after the first click. </paragraph>
                              <content styleCode="bold">Important: </content>If you do not hear a “click” when you press the gray activation button, make sure that the autoinjector is pressed down against the skin, then try again. </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM15"/>
                              <paragraph>
                                 <content styleCode="bold">Figure K</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">5.3</content> Hold the autoinjector down against the skin for at least 10 seconds to make sure you get the full dose of BREKIYA (See Figure L).</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Note:</content> You may hear a second “click”, which means you are close to the end of the injection. Whether or not you hear a second “click” you must hold down the autoinjector against your skin for at least 10 seconds. </paragraph>
            Do not lift up the autoinjector early. </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM16"/>
                              <paragraph>
                                 <content styleCode="bold">Figure L</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">5.4</content> Make sure the injection is finished by looking at the viewing window. The viewing window will turn completely blue (See Figure M) when the full dose of BREKIYA has been given. </paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Note: </content>Even if the inspection window is not completely blue, do not try to use the autoinjector again.</paragraph>
             </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM17"/>
                              <paragraph>
                                 <content styleCode="bold">Figure M</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Throwing Away (Disposing of) BREKIYA Autoinjector</content> </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Step 6: Lift and Throw away (dispose of)</content> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">6.1</content> Lift the autoinjector straight up, away from the skin. The white safety guard will drop down and lock over the needle (See Figure N).  </paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                              </paragraph>
                              <content styleCode="bold">Note:</content> If you think that you have not received the full dose, do not repeat the injection using a new autoinjector. Call your healthcare provider right away for assistance. </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <renderMultiMedia referencedObject="MM18"/>
                              <paragraph>
                                 <content styleCode="bold">Figure N</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">6.2</content> Throw away (dispose of) the used autoinjector into a FDA-cleared sharps disposal container (See Figure O). </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not </content>throw away (dispose of) the autoinjector into household trash. </paragraph>
             </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">
                                    <renderMultiMedia referencedObject="MM19"/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure O</content> </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">6.3 </content>Treat the injection site as needed (See Figure P). It is normal to see a drop of blood or medicine at the injection site. It will not affect your dose.  </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">
                                    <renderMultiMedia referencedObject="MM20"/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure P</content> </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Additional Information on how to Throw Away (Dispose of) BREKIYA</content> </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not throw away (dispose of) loose needles and syringes in your household trash.</content>
                                 </item>
                                 <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: </item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>made of a heavy-duty plastic,</item>
                                 <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, </item>
                                 <item>upright and stable during use, </item>
                                 <item>leak-resistant, and</item>
                                 <item>properly labeled to warn of hazardous waste inside the container. </item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: <linkHtml href="http://www.fda.gov/safesharpsdisposal">http://www.fda.gov/safesharpsdisposal</linkHtml>
                                 </item>
                                 <item>Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.</item>
                              </list>
                              <paragraph>Distributed by:</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Amneal Specialty, a division of Amneal Pharmaceuticals LLC</content>
                              </paragraph>
                              <paragraph>Bridgewater, NJ  08807<br/>
                                 <br/>
            Manufactured by:</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Amneal Pharmaceuticals Pvt. Ltd.</content>
                              </paragraph>
                              <paragraph>Ahmedabad 382213, INDIA<br/>
                                 <br/>
                                 <content styleCode="bold">For more information or to report side-effects, call 1-877-835-5472.<br/>
                                    <br/>
                                 </content>Rev. 05-2025-00 </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Instructions for Use have been approved by the U.S. Food and Drug Administration                                                                                                                     Issued: 05/2025</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250515"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM14">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM15">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM16">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM17">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM18">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM19">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM20">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brekiya---dihydroergotamine-mesylate-injection-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3d87df18-2dda-4d16-b4be-ede5d6584ea0">
               <id root="cb008dad-2b07-4101-bece-27259face39d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250515"/>
               <component>
                  <section ID="LINK_195fabdc-2b09-4ae2-9cf9-e220cbd35553">
                     <id root="3a582d0d-aa01-49ad-a21d-7f4840624741"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">NDC 64896-509-01</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">BREKIYA<sup>®</sup> (dihydroergotamine mesylate) injection, 1 mg/mL</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Rx only</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Autoinjector Label</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Amneal Pharmaceuticals LLC</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM21"/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                     <component>
                        <observationMedia ID="MM21">
                           <text>1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="brekiya---dihydroergotamine-mesylate-injection-21.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d38560ea-3e24-4f17-99f9-ec7d32e7419d">
                     <id root="5ef98753-1283-441a-b45a-47cca1c0cf70"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">NDC 64896-509-01</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">BREKIYA<sup>®</sup> (dihydroergotamine mesylate) injection, 1 mg/mL</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Rx only</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Pouch</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Amneal Pharmaceuticals LLC</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM22"/>
                     </text>
                     <effectiveTime value="20250515"/>
                     <component>
                        <observationMedia ID="MM22">
                           <text>1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="brekiya---dihydroergotamine-mesylate-injection-22.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_73d2e0d8-7fff-4be8-ad6d-797f7ad71787">
                     <id root="95f482ba-cba8-4885-95eb-a39850f74d95"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">NDC 64896-509-02</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">BREKIYA<sup>®</sup> (dihydroergotamine mesylate) injection, 1 mg/mL</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Rx only</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Carton</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Amneal Pharmaceuticals LLC</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM23"/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250515"/>
                     <component>
                        <observationMedia ID="MM23">
                           <text>1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="brekiya---dihydroergotamine-mesylate-injection-23.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>